Dr. Tom Okarma, for one.
Despite across the board enthusiasm for the stem cell breakthrough announced yesterday, Dr. Okarma, president and chief executive of Geron Corporation, nastily dismissed the news, saying the new techniques were not likely "to bear any fruit."
By the way, Geron Corporation is a California biotech drug company that has spent $100 million on human embryonic stem cell research.
And, oh yes; the company's stock fell six percent Tuesday following the research announcement.
I think I see a reason for Dr. Okarma's distress.